DexCom, Inc.
DXCM
$0.00
-0.68%
DexCom, Inc. is a healthcare company that designs and commercializes continuous glucose monitoring (CGM) systems for diabetic patients. It is a leader in the medical devices industry, with core advantages in CGM technology and integration with automated insulin delivery systems.
DXCM
DexCom, Inc.
$0.00
Investment Opinion: Should I buy DXCM Today?
Based on a synthesis of the data, the objective assessment is a Hold. The company's excellent fundamentals, including 13% revenue growth, >20% net margins, and a strong cash flow profile, support a long-term bullish thesis. However, the high absolute valuation (P/E 31x) and severe recent technical breakdown create significant near-term uncertainty and risk of further downside. Investors should wait for either a more attractive valuation entry point or a clear reversal in price momentum before establishing new positions.
Sign up to view all
DXCM 12-Month Price Forecast
The investment case is balanced. The exceptional business quality is undeniable, but it is fully priced in, and the stock lacks positive technical catalysts in the near term. The base case of moderate appreciation seems most probable.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on DexCom, Inc.'s 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
8 analysts
Implied Upside
—
vs. current price
Analyst Count
8
covering this stock
Price Range
$0 - $0
Analyst target range
Data not available. The provided inputs include recent analyst rating actions (e.g., 'Buy' and 'Outperform' from several firms), but do not contain consensus target price data, ratings distribution percentages, or a sufficient number of analyst estimates to summarize a Wall Street consensus. Therefore, no sufficient analyst coverage data is available for a detailed summary.
Bulls vs Bears: DXCM Investment Factors
DexCom presents a dichotomy of strong underlying fundamentals against weak recent price action. The company is growing revenue profitably and has a robust balance sheet, but the stock is experiencing significant selling pressure and trades at high absolute valuation multiples, creating a volatile investment proposition.
Bullish
- Strong Revenue Growth: Q4 revenue grew 13.1% YoY, showing robust demand.
- High Profitability Margins: Q4 net margin of 21.2% and operating margin of 25.6%.
- Solid Financial Position: Strong free cash flow of $1.08B TTM and low debt-to-equity of 0.51.
- Attractive PEG Ratio: PEG of 0.66 suggests undervaluation relative to growth.
Bearish
- Sharp Recent Price Decline: Stock down 15.7% in 1 month, underperforming the market.
- High Valuation Multiples: Trailing P/E of 31.0x and P/S of 5.6 are elevated.
- High Market Volatility (Beta): Beta of 1.526 indicates amplified price swings vs. market.
- Significant Short Interest: Short ratio of 3.89 suggests notable bearish sentiment.
DXCM Technical Analysis
The stock has been in a volatile downtrend over the past six months, with the price declining from approximately $66 in early October 2025 to around $62 by late March 2026. The 1-month and 3-month price changes are -15.70% and -7.69%, respectively, significantly underperforming the broader market (SPY) which fell -7.87% and -7.32% over the same periods, indicating relative weakness.
Short-term performance has been weak, with the stock price falling from about $74 in late January to $61.90 by March 30, 2026. This represents a sharp correction of over 16% from its recent high, highlighting significant selling pressure and volatility during this period.
The current price of $61.90 is well below its 52-week high of $89.98 and closer to its 52-week low of $54.11, trading near the lower end of its annual range. The stock's beta of 1.526 indicates it is more volatile than the overall market, which has contributed to its amplified price swings.
Beta
1.53
1.53x market volatility
Max Drawdown
-39.0%
Largest decline past year
52-Week Range
$54-$90
Price range past year
Annual Return
-7.4%
Cumulative gain past year
| Period | DXCM Return | S&P 500 |
|---|---|---|
| 1m | -15.5% | -3.7% |
| 3m | -6.0% | -4.1% |
| 6m | -7.0% | -2.1% |
| 1y | -7.4% | +16.1% |
| ytd | -6.3% | -3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DXCM Fundamental Analysis
Revenue for Q4 2025 was $1.26 billion, representing a 13.1% year-over-year growth from Q4 2024. Net income for the quarter was $267.3 million, translating to a net margin of 21.2%, showing strong and improving profitability from the prior year's Q4 net margin of 13.6%.
The company maintains a solid financial position with a debt-to-equity ratio of 0.51 and a current ratio of 1.88, indicating manageable leverage and sufficient short-term liquidity. Free cash flow for the trailing twelve months was a robust $1.08 billion, providing significant financial flexibility for operations and investments.
Operational efficiency is strong, with a return on equity (ROE) of 30.5% and a return on assets (ROA) of 8.9% as of the latest data. The quarterly gross margin of 62.9% and operating margin of 25.6% in Q4 2025 demonstrate effective cost management and a highly profitable business model.
Quarterly Revenue
$1.3B
2025-12
Revenue YoY Growth
+0.13%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DXCM Overvalued?
Given the company's positive net income, the primary valuation metric used is the P/E ratio. DexCom trades at a trailing P/E of approximately 31.0x and a forward P/E of about 20.7x, based on the provided data. The forward P/E suggests a lower valuation relative to recent earnings growth expectations.
Compared to industry averages, which are not provided in the data, a direct peer comparison cannot be made. However, the company's price-to-sales (P/S) ratio of 5.6 and price-to-cash-flow (P/CF) ratio of 18.0 provide additional context. The PEG ratio of 0.66, if accurate, could indicate the stock is potentially undervalued relative to its expected earnings growth rate.
PE
31.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -671x~231x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.7x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is valuation compression, as the stock's high trailing P/E of 31.0x makes it vulnerable to negative earnings revisions or a shift in market sentiment away from growth stocks. High short interest (ratio 3.89) and a beta of 1.526 indicate the stock is a battleground and prone to sharp swings, which has been evident in its 16% correction from recent highs. Competitive and regulatory risks in the medical device sector are perennial, though DexCom's leadership position mitigates this somewhat. Furthermore, the stock's technical weakness, trading near its 52-week low after a significant downtrend, suggests momentum risk may persist in the near term.
FAQ
Key risks include: 1) Valuation Risk: High P/E of 31x makes the stock sensitive to earnings misses or rising interest rates. 2) Volatility Risk: A beta of 1.526 means it is ~50% more volatile than the market. 3) Sentiment Risk: High short interest (ratio 3.89) can fuel downward pressure. 4) Technical Risk: The stock is in a downtrend and trading near its 52-week low of $54.11.
The 12-month outlook presents a base case target range of $65 to $75, implying roughly 5-21% upside from $61.90. This assumes the company meets analyst EPS expectations near $5.02, supporting a forward P/E around 20.7x. A bull case (25% probability) could see a run towards $90, while a bear case (15% probability) could test the 52-week low near $54.
The valuation sends mixed signals. The trailing P/E of 31.0x appears high on an absolute basis, suggesting the stock is fully valued. However, the forward P/E of 20.7x and a PEG ratio of 0.66, if reliable, point to potential undervaluation relative to its earnings growth rate. Overall, it is fairly valued to slightly overvalued based on current earnings, with the premium justified by its high-quality growth profile.
At the current price of $61.90, DXCM is assessed as a Hold, not a strong Buy. The company's fundamentals are excellent with 13.1% revenue growth and a 21.2% net margin, but the stock's high trailing P/E of 31.0x and severe recent underperformance (-15.7% in 1 month) present significant near-term risk. Investors should wait for a more attractive entry point or a stabilization in price momentum.
DXCM is more suitable for long-term investors who can tolerate high volatility. The company's leadership in CGM technology and strong financials support a multi-year growth story. Short-term traders face significant headwinds from the stock's high beta, negative momentum, and valuation concerns. Patient investors may be rewarded, but should be prepared for a bumpy ride.